Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Commentary: Guideline for male testosterone therapy: a clinician's perspective.

Morgentaler A.

J Clin Endocrinol Metab. 2007 Feb;92(2):416-7. Review. No abstract available.

PMID:
17284642
2.

Commentary: Guideline for male testosterone therapy: a regulatory perspective.

Shames D, Gassman A, Handelsman H.

J Clin Endocrinol Metab. 2007 Feb;92(2):414-5. Review. No abstract available.

PMID:
17284641
3.

Commentary: Guideline for male testosterone therapy: a European perspective.

Wu FC.

J Clin Endocrinol Metab. 2007 Feb;92(2):418-9. Review. No abstract available.

PMID:
17284643
4.

Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.

Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M.

J Endocrinol Invest. 2015 Jan;38(1):103-12. doi: 10.1007/s40618-014-0155-9. Review.

5.

Testosterone replacement therapy: take an informed, individualized approach.

Coplan B, Spiegel J, Bleaman I, Roch J.

JAAPA. 2011 Jan;24(1):42-7. Review. No abstract available.

PMID:
21261147
6.

Clinical use of androgens.

Snyder PJ.

Annu Rev Med. 1984;35:207-17. Review.

PMID:
6372655
7.

Late-onset male hypogonadism and testosterone replacement therapy in primary care.

Brunton SA, Sadovsky R.

J Fam Pract. 2010 Jul;59(7 Suppl):S1-8. Review.

PMID:
20625573
8.

Testosterone replacement therapy: current trends and future directions.

Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC.

Hum Reprod Update. 2004 Sep-Oct;10(5):409-19. Review.

PMID:
15297434
9.

[Hypogonadism and cardiovascular diseases in men].

[No authors listed]

Ter Arkh. 2011;83(10):61-7. Review. Russian.

PMID:
22185029
10.

Testosterone administration in older men.

Matsumoto AM.

Endocrinol Metab Clin North Am. 2013 Jun;42(2):271-86. doi: 10.1016/j.ecl.2013.02.011. Review.

PMID:
23702401
11.

FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.

Meza J, Weaver K, Martin S.

Am Fam Physician. 2013 Oct 15;88(8):Online. Review. No abstract available.

12.

Testosterone replacement in men.

Beg S, Al-Khoury L, Cunningham GR.

Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):364-70. doi: 10.1097/MED.0b013e328305081a. Review.

PMID:
18594278
13.

[Prostate carcinoma and testosterone: risks and controversies].

Rhoden EL, Averbeck MA.

Arq Bras Endocrinol Metabol. 2009 Nov;53(8):956-62. Review. Portuguese.

14.

Testosterone therapy and prostate carcinoma.

Rhoden EL, Averbeck MA.

Curr Urol Rep. 2009 Nov;10(6):453-9. Review.

PMID:
19863857
15.

Clinical review 34: Androgen treatment of hypogonadal men.

Bhasin S.

J Clin Endocrinol Metab. 1992 Jun;74(6):1221-5. Review. No abstract available.

PMID:
1592862
16.

Androgen replacement in men with hypogonadism and erectile dysfunction.

Albrecht-Betancourt M, Hijazi RA, Cunningham GR.

Endocrine. 2004 Mar-Apr;23(2-3):143-8. Review.

PMID:
15146093
17.

Androgen replacement therapy in aging men.

Katz A.

Nurse Pract. 2004 Oct;29(10):58-64. Review. No abstract available.

PMID:
15489672
18.

Testosterone metabolism and replacement therapy in patients with end-stage renal disease.

Johansen KL.

Semin Dial. 2004 May-Jun;17(3):202-8. Review.

PMID:
15144546
19.

Hormonal therapy of male hypogonadism.

Matsumoto AM.

Endocrinol Metab Clin North Am. 1994 Dec;23(4):857-75. Review.

PMID:
7705324
20.

Testosterone replacement therapy for late-onset hypogonadism.

Cunningham GR.

Nat Clin Pract Urol. 2006 May;3(5):260-7. Review.

PMID:
16691239

Supplemental Content

Support Center